You just read:

Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody

News provided by

Sorrento Therapeutics, Inc.

16 May, 2016, 07:00 ET